Picroliv for non-alcoholic fatty liver disease
Part of Digestive system, Hormones & metabolism clinical trials.
This study tests a plant-based medicine called Picroliv for people with non-alcoholic fatty liver disease (NAFLD). It aims to see if it is safe and can reduce fat in the liver.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old.
- You have at least 10% liver fat on an MRI scan.
- Your blood counts and thyroid levels are in a safe range.
- You do not drink heavily (more than a glass of wine a day for women, two for men).
- You are not pregnant, breastfeeding, or planning to become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests special food products made from plant protein to see if they are well-tolerated and if they can improve your cholesterol and fat levels in the blood. If you have fatty liver disease, this could be a way to improve your health through diet.
This is an early-stage study testing a new medicine called PF-08653944 in healthy adults and in people with varying degrees of liver function problems. The goal is to understand how the medicine works in the body and how liver function affects how the body processes it.
This trial tests a new medication for people with fatty liver disease. It will see if the drug can reduce liver fat and improve liver health over several doses.
This trial tests whether a probiotic supplement can improve liver health and metabolism in adults with early signs of fatty liver or related conditions. It may help reduce fat in the liver and improve blood sugar and blood pressure.
This trial tests whether taking probiotics plus making lifestyle changes can improve fatty liver and metabolic health. You may qualify if you have liver fat and at least one sign of metabolic problems like high blood sugar or high blood pressure.
This study tests whether a new drug called AZD2389 is safe and well-tolerated in adults with steatotic liver disease (fatty liver) that has progressed to advanced scarring. The trial aims to see if this drug might help slow or improve liver damage in people with this condition.
Hear when a new Non Alcholic Fatty Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.